P38 kinase in gastrointestinal cancers

Cancer Gene Ther. 2023 Sep;30(9):1181-1189. doi: 10.1038/s41417-023-00622-1. Epub 2023 May 29.

Abstract

Gastrointestinal cancers are a leading cause of cancer morbidity and mortality worldwide with 4.2 million new cases and 3.2 million deaths estimated in 2020. Despite the advances in primary and adjuvant therapies, patients still develop distant metastases and require novel therapies. Mitogen‑activated protein kinase (MAPK) cascades are crucial signaling pathways that regulate many cellular processes, including proliferation, differentiation, apoptosis, stress responses and cancer development. p38 Mitogen Activated Protein Kinases (p38 MAPKs) includes four isoforms: p38α (MAPK14), p38β (MAPK11), p38γ (MAPK12), and p38δ (MAPK13). p38 MAPK was first identified as a stress response protein kinase that phosphorylates different transcriptional factors. Dysregulation of p38 pathways, in particular p38γ, are associated with cancer development, metastasis, autophagy and tumor microenvironment. In this article, we provide an overview of p38 and p38γ with respect to gastrointestinal cancers. Furthermore, targeting p38γ is also discussed as a potential therapy for gastrointestinal cancers.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Gastrointestinal Neoplasms* / genetics
  • Humans
  • Mitogen-Activated Protein Kinase 11* / metabolism
  • Mitogen-Activated Protein Kinase 12 / genetics
  • Mitogen-Activated Protein Kinase 12 / metabolism
  • Mitogen-Activated Protein Kinase 13 / metabolism
  • Signal Transduction
  • Tumor Microenvironment
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Mitogen-Activated Protein Kinase 11
  • Mitogen-Activated Protein Kinase 12
  • Mitogen-Activated Protein Kinase 13
  • p38 Mitogen-Activated Protein Kinases